Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392220 | 0.80 | GSK3A (0.38) | GSK3AGSK3BIP6K1CHEK1PIM1 | |
| SCHEMBL8212169 | 0.78 | PARP1 (0.54) | IP6K1SMN1; SMN2PARP1CHEK1PIM1 | |
| SCHEMBL30016751 | 0.75 | PARP1 (0.54) | IP6K1SMN1; SMN2PRMT5WDR77ALDH1A1 | |
| SCHEMBL393560 | 0.75 | PARP1 (0.54) | IP6K1SMN1; SMN2PRMT5WDR77ALDH1A1 | |
| SCHEMBL29382832 | 0.71 | GSK3A (0.57) | GSK3AGSK3BPRMT5WDR77CHEK1 | |
| SCHEMBL18239676 | 0.71 | GSK3A (0.39) | GSK3AGSK3BPDGFRBKDRLPL | |
| SCHEMBL3225882 | 0.69 | PRMT5 (0.40) | GSK3AGSK3BPRMT5WDR77LPL | |
| SCHEMBL2966812 | 0.69 | GSK3A (0.43) | GSK3AGSK3BPRMT5WDR77PDGFRB | |
| SCHEMBL21989355 | 0.69 | GSK3A (0.38) | GSK3AGSK3BPRMT5WDR77PDGFRB | |
| SCHEMBL2171645 | 0.69 | LPL (0.42) | PRMT5WDR77PARP1CHEK1LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| EP-2057156-B1 | 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2017-02-01 | — | — | EP | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8435985-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MENEAR KEITH (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2057156-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1333/4885GSK3B 1151/4885IP6K1 251/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1333/4885GSK3B 1151/4885IP6K1 251/4885 |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1333/4885GSK3B 1151/4885IP6K1 251/4885 |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1333/4885GSK3B 1151/4885IP6K1 251/4885 |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1251/4885GSK3B 1087/4885IP6K1 223/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | GSK3A 3032/4885GSK3B 3092/4885IP6K1 2161/4885 |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | GSK3A 1333/4885GSK3B 1151/4885IP6K1 251/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | GSK3A 2430/4885GSK3B 1798/4885IP6K1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.